IXICO announces an expanded contract for its imaging services with Vaccinex

Supports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's disease

We are delighted to announce an award of a contract to provide imaging services for Vaccinex Inc.'s planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer's disease (AD). This will build on the our existing contract to support Vaccinex's Phase II study of pepinemab in the Huntington's disease SIGNAL trial, which was previously announced in September 2017.  

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"This AD trial, called SIGNAL - AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes.

"We are delighted that Vaccinex has chosen to expand our partnership to support its diversification into Alzheimer's disease. Our existing project with Vaccinex, the SIGNAL trial, is in Huntington's disease (HD) to study the safety and efficacy of pepinemab, where the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas; this contract was initiated in 2017 and the new award is a great testament to the achievements of our two organisations working diligently together since then. We are pleased to be part of Vaccinex's effort to bring hope to AD patients and their families."

This contract does not have significant impact on management's expectations of perfomance for the year.

About Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in non-small cell lung cancer and Huntington's disease. Vaccinex is based in Rochester, New York.

Date: 16/03/2020